stockrowC4 Therapeutics, Inc. (CCCC) vs Lyell Immunopharma, Inc. (LYEL)
- C4 Therapeutics, Inc. CCCC 3.12 +5.76%
- Lyell Immunopharma, Inc. LYEL 14.82 −1.20%
C4 Therapeutics, Inc. and Lyell Immunopharma, Inc. are both Biotechnology companies. C4 Therapeutics, Inc. and Lyell Immunopharma, Inc. are of similar size ($367.6M and $362.9M). C4 Therapeutics, Inc. grew revenue faster over the last twelve months: 7.20% against −63.4%. C4 Therapeutics, Inc. has the higher net margin (−282.2% vs −1,701,066.7%) and the higher return on invested capital (−280.0% vs −1,070.8%). Across the 16 metrics below, C4 Therapeutics, Inc. leads on 14 and Lyell Immunopharma, Inc. on 2.
Valuation
Profitability
| Metric | CCCC | LYEL | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 100.00% | 68.51% |
| Operating margin | (315.86%) | (1,783,580.00%) | 0.00% |
| Net margin | (282.22%) | (1,701,066.67%) | 0.00% |
| Free cash flow margin | (246.71%) | (928,333.33%) | 0.00% |
| Return on equity | (47.62%) | (97.79%) | (51.96%) |
| Return on assets | (30.50%) | (74.85%) | (46.06%) |
| Return on invested capital | (279.99%) | (1,070.83%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack